Quadrant stock closed at Rs 319.50 in the previous session. Market cap of the firm stood at Rs 1278 crore.

Pharmacosmos initiates phase III clinical trial of trilaciclib in limited-stage small cell lung cancer MORRISTOWN, NJ, ...

TACTI-004 planned ~756 patients across >150 sites and enrolled 378 by February 2026, including squamous and nonsquamous NSCLC irrespective of PD-L1 status. Randomization compared eftilagimod alfa plus ...

BioMarin Pharmaceutical's (BMRN) shares fell on Monday after the company said it would discontinue dosing and enrollment in ...

Throughout the year, the Company reported significant positive preclinical findings for SIL204 across eight KRAS mutations ...

Patients with HER2-positive breast cancer in the FLAMINGO-01 phase 3 clinical trial are seeing a continued reduction in recurrence rates, Greenwich LifeSciences, Inc. has reported. The preliminary ...

Corvus Pharmaceuticals (NASDAQ:CRVS) outlined expanding clinical plans for its selective ITK inhibitor soquelitinib while reporting higher research and development spending for 2025, reflecting a ...

Analysts remain intrigued by aleniglipron’s potential in the oral GLP-1RA market, though they note it is too early to compare the drug’s efficacy to Eli Lilly’s orforglipron.

Structure Therapeutics (GPCR) stock jumped 10% after its GLP-1 pill aleniglipron posted 16.3% weight loss, outperforming Lilly and Novo's oral candidates.

DYNAMIKA™ delivers SOC 2 Type II–certified, AI‑driven imaging workflows, giving pharma and biotech secure, compliant ...

Bicycle Therapeutics is letting more air out of its operations, with plans to deflate its employee count by about 30% and shelve its lead anti-cancer drug conjugate. The reprioritization is meant to ...

Structure Therapeutics’ aleniglipron Phase 2 shows ~16% placebo-adjusted weight loss; a best-in-class oral GLP-1 with strong ...